Valeant Pharmaceuticals Intl Inc (TSE:VRX) (NYSE:VRX) has received a consensus recommendation of “Hold” from the five analysts that are covering the company, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is C$22.50.
Several analysts have weighed in on VRX shares. TD Securities boosted their price objective on Valeant Pharmaceuticals Intl to C$26.00 and gave the stock a “hold” rating in a report on Wednesday, July 12th. Royal Bank Of Canada dropped their price objective on Valeant Pharmaceuticals Intl to C$22.50 and set a “sector perform” rating for the company in a report on Friday, October 20th.
In other news, Director John Paulson sold 24,700 shares of the company’s stock in a transaction dated Wednesday, August 9th. The stock was sold at an average price of C$14.66, for a total value of C$362,102.00. Also, Director Schutter Richard Urbain De purchased 4,900 shares of the stock in a transaction dated Monday, August 21st. The stock was bought at an average cost of C$14.35 per share, with a total value of C$70,315.00.
TRADEMARK VIOLATION NOTICE: This news story was originally published by Community Financial News and is the sole property of of Community Financial News. If you are reading this news story on another site, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be accessed at https://www.com-unik.info/2017/10/30/valeant-pharmaceuticals-intl-inc-vrx-given-consensus-recommendation-of-hold-by-brokerages.html.
Valeant Pharmaceuticals Intl (VRX) opened at 14.64 on Monday. Valeant Pharmaceuticals Intl has a 1-year low of $11.20 and a 1-year high of $32.50. The firm’s 50-day moving average is $16.89 and its 200 day moving average is $17.57. The firm’s market cap is $5.10 billion.
About Valeant Pharmaceuticals Intl
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
What are top analysts saying about Valeant Pharmaceuticals Intl Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Valeant Pharmaceuticals Intl Inc and related companies.